Cargando…
Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. Wi...
Autores principales: | Beran, Jiří, Špajdel, Marián, Slíva, Jiří |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619495/ https://www.ncbi.nlm.nih.gov/pubmed/34835052 http://dx.doi.org/10.3390/v13112246 |
Ejemplares similares
-
Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic
por: Beran, Jiří, et al.
Publicado: (2020) -
Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study
por: Beran, Jiří, et al.
Publicado: (2016) -
Correction: Beran et al. Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic. Pathogens 2020, 9, 1055
por: Beran, Jirí, et al.
Publicado: (2021) -
Genotoxicity and Mutagenicity of Inosine Pranobex
por: Tobólska, Sylwia, et al.
Publicado: (2018) -
Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases
por: Sliva, Jiri, et al.
Publicado: (2019)